Reveal Biosciences

What Reveal Biosciences does

Reveal Biosciences, operating under the legal name CellCarta, is a global contract research organization (CRO) providing integrated precision medicine laboratory services to pharmaceutical and biotechnology companies. The firm delivers biomarker development and validation, immune monitoring, proteomics, genomics, histopathology, bioinformatics and biostatistics, regulatory and companion diagnostic (CDx) services, and sample management and logistics across the therapeutic development lifecycle from discovery through clinical phases. Its proprietary technology stack includes the CellEngine® cytometry analysis software and the Antigen Atlas™ proprietary antigen database, complemented by multi-vendor platforms such as Ella (automated ELISA multiplexing), Olink PEA, RareCyte, Mass Cytometry (CyTOF), Mass Spectrometry, MSD, Nanostring, flow cytometry, spatial biology, and single-cell sequencing.

The company operates CAP-accredited laboratory facilities, including a site in Jining, China that supports HGRAC regulatory submissions, and serves therapeutic areas spanning oncology, immunology, neurosciences, infectious diseases, cell therapy, antibody-drug conjugates, and targeted protein degraders. Customer relationships are structured as multi-year, quote-based enterprise contracts sold through direct B2B engagement, scientific consultation, and conference-driven lead generation. A March 2025 strategic collaboration with Leica Biosystems combines CellCarta's CDx capabilities with Leica's pathology expertise to advance companion diagnostic development. Note: the firmographic header identifies the company as Reveal Biosciences (founded 2012, San Diego, 11-50 employees, "AI to Diagnose Disease From Pathology Images"), while the detailed source material describes CellCarta as the operating legal entity; this reconciliation gap represents a material data quality issue for diligence.

The business model is fee-for-service professional services revenue tied to therapeutic development programs. Funding history includes a 2019 Round 2 led by Intel Capital with participation from GNI Japan and PP Capital; no subsequent funding, revenue, or headcount trend data is disclosed. The firm is private, headquartered in Canada (per the CellCarta entity), with global operating geographies emphasizing Asia-market service.

Name

Reveal Biosciences

Legal name

CellCarta

Website

https://revealbio.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Reveal Biosciences (operating as CellCarta) is a global contract research organization providing integrated biomarker, immune monitoring, proteomics, genomics, histopathology, and companion diagnostic services to pharmaceutical and biotech clients across the therapeutic development lifecycle.

Ownership category

akta.pro rank

Product category

Digital Pathology Software

NAICS

Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• AI pathology diagnosis
• Digital pathology software
• Medical imaging AI
• Computational pathology
• Pathology image analysis

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service CRO model providing laboratory testing, biomarker analysis, and regulatory support to pharmaceutical and biotech companies across all phases of drug development.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Reveal Biosciences develops artificial intelligence software designed to diagnose disease from pathology images. The company applies machine learning and computer vision to medical pathology specimens to support automated disease detection and diagnostic workflows for healthcare and life sciences organizations.

Product overview

CellCarta is a global contract research organization (CRO) offering a comprehensive suite of precision medicine testing services. The company's portfolio consists of integrated service categories including Biomarker Solutions (clinical and discovery biomarkers), Immune Monitoring, Proteomics, Genomics, Histopathology, Data Analysis (including CellEngine® Software and Antigen Atlas™ Database), Regulatory Expertise (companion diagnostics), and Lab Logistic Services. These services are delivered through various technology platforms including Ella™ (automated ELISA multiplexing), Olink™ PEA Technology, RareCyte, Spatial Biology, and Single-Cell Sequencing. The company provides end-to-end support across all phases of therapeutic development, with particular expertise in oncology, immunology, neurosciences, infectious diseases, cell therapy, and antibody-drug conjugates.

Differentiator

Problem solved

Functional benefit

Brands

• CellEngine®: Comprehensive cytometry analysis software
• Antigen AtlasTM Database

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Leica BiosystemscoreStrategic or Co-development Partner · 24 March 2025Strategic collaboration for advancing precision diagnosis and treatment. Co-promoting the development of companion diagnostics combining CellCarta's CDx services with Leica Biosystems' pathology expertise.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NeoGenomics: Clinical oncology-focused lab services provider with strong pathology, IHC, NGS, and CDx capabilities; competes for the same oncology biomarker and CDx engagements.
• IQVIA: Largest global CRO with deep biomarker, central lab, and clinical development capabilities; directly competes for the same pharma/biotech outsourced testing and biomarker work that CellCarta targets.
• Labcorp Drug Development (formerly Covance): Global clinical and central laboratory CRO offering biomarker, genomic, and companion diagnostic services — directly comparable to CellCarta's integrated testing services model.
• ICON plc: Global CRO with central laboratory and biomarker capabilities (post-PRA Health and Symphony Health acquisitions); competes for the same multi-modality clinical biomarker engagements.
• Charles River Laboratories: Preclinical and clinical CRO with discovery, biomarker, and cell therapy services; directly comparable in offering preclinical-to-clinical workflow support to pharma/biotech sponsors.
• Eurofins Scientific: Global bioanalytical and clinical testing services network with strong genomic, proteomic, and histopathology offerings; overlaps with CellCarta across biomarker and CDx testing.
• Precision for Medicine: Specialty CRO focused on biomarker-driven clinical development and CDx, serving pharma/biotech across oncology and rare disease — a close peer in scale and therapeutic focus.
• Q² Solutions: Joint venture central laboratory offering genomics, proteomics, flow cytometry, and bioanalytical services; directly comparable to CellCarta in biomarker and immune monitoring services.

Broad incumbents

• Bio-Techne: Large life science tools and proteomics company with reagent and assay platforms (including protein biomarker technologies like Ella-adjacent offerings); adjacent competitor in proteomic biomarker services.

Others

• Leica Biosystems: Strategic partner of CellCarta and global leader in pathology and digital pathology instrumentation; adjacent rather than competing, but highly relevant given the announced CDx collaboration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/CellCarta
• LinkedInlinkedin.com/company/cellcarta
• Xx.com/revealbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reveal Biosciences